Topics
- Distribution strategies and Pricing mechanism of biosimilars in China
- Regulatory pathways and guidelines for biosimilars in China
- Scale-up for downstream processing
- Best practices in process development and engineering for mAbs and vaccines
- Case studies on novel or next generation biologics
- Innovative cell lines for mAb and vaccine development
- IP management of biologic products in China
- WHO pre-qualification for Chinese vaccines and biologics
- Optimizing upstream and downstream processes
- Implementing quality control throughout entire bioprocess
- Analytical methods to prove biosimilarity
- Successful case studies and Partnership models with Chinese biologic companies
Who should Attend
Attendees from biopharmaceutical and biotechnology companies as well as academia, including CEOs, MDs, VPs and directors of manufacturing, general managers, business unit heads, scientists and engineers.
